Anti-Viral Drugs Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Report Description<br />
people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries<br />
with a high burden of HIV, two out of three people in need are receiving treatment, and<br />
two out of three positive pregnant women are receiving antiretroviral drugs to prevent<br />
HIV transmission to their infants.<br />
<strong>Anti</strong>-viral <strong>Drugs</strong> <strong>Market</strong>: Regional Overview<br />
Region wise, the global anti-viral drugs market is classified into regions namely, North<br />
America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East<br />
and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or<br />
China, the death rate among people living with HIV has decreased by 80%. In 2015, in<br />
India the number of people living with HIV were 2.1 Mn and in U.S. the number was<br />
around 1.2 Mn in the year 2013.<br />
Browse Full Report@<br />
http://www.futuremarketinsights.com/reports/anti-viral-drugs-market<br />
<strong>Anti</strong>-viral <strong>Drugs</strong> <strong>Market</strong>: Key Players<br />
Some of the key players in global anti-viral drugs market, which are focusing on general<br />
molecular mechanisms of antiviral drugs rather than therapies for individual viruses,<br />
include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca,<br />
Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.
Change language